In 1948, he returned to Poland and was vicar of various parishes in Cracow as well as chaplain for the students until 1951, when he resumed his studies in philosophy and theology. He defended a he defended a thesis on evaluation of the possibility of founding a Catholic ethic on the ethical system of Max Scheler at Lublin Catholic University. Made him a professor of moral theology and social ethics in the major seminary of Cracow and in the Faculty of Theology of Lublin.
Crossing the Threshold has also published five books: Crossing the Threshold of Hope , Gift and Mystery: On the 50th anniversary of my priestly ordination , -iptych – Meditations , a book of poems , let us make our way and Memory and Identity .
The results of the first published results of analyzes of data from Framingham share are were free since the extensive Web-based dataset of genetic and clinical data are available to researchers worldwide in October 2007. Framingham share includes data from more than 9,300 participants from three generations. The Framingham Heart Study the NHLBI NHLBI in collaboration with Boston University School of Medicine and Boston University School of Public Health..Merrimack Pharmaceuticals announced fact that five patients therapy at a time I got clinical trials the combination of MM-111 multi default treatment therapies on patient with advanced HER2-positive solid tumors.
‘. Source: Merrimack Pharmaceuticals.. MM – are bi – specific antibody, said tumor cells overexpression ErbB2/HER2 seeks. MM – 111 is designed to be signaling between ErbB2/HER2 ErbB3/HER3 deactivating and thus inhibit the downstream signal is processing, including phosphatidylinositol 3 – kinase pathway, and preventing cancer proliferation. In this study, Merrimack is evaluating whether MM-111 could be safe default therapy be used to HER2-positive cancers will be added treated. This study could. Also some preliminary evidence of activity in patients with advanced / metastatic HER2-positive disease, an area of high medical need for it only a limited treatment options more than 1,400 be historical more aggressively and contribute a poorer prognosis than other type of solid tumors,’says Clet Niyikiza, Executive Vice President of Development, Merrimack Pharmaceuticals.